|
|
Blood, Vol. 104, Issue 6, 1888-1893, September 15, 2004
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
Blood Seldin et al.
104: 1888
Supplemental materials for: Seldin et al, Vol 104, Issue 6, 1888-1893
Files in this Data Supplement:
- Table S1. Quantitative data in support of Figure 1 (PDF file, 96 KB) -
This table provides the values for the mean scores on the SF-36 scales for (1) all 544 patients with AL amyloidosis evaluated at Boston Medical Center; (2) the 251 patients treated with high-dose melphalan and autologous stem cell transplantation; and (3) the 210 patients who did not meet protocol clinical criteria and were ineligible for such treatment. These are compared by one-sample t tests with US population norms for individuals in the same 10-year age ranges, and P values indicate those scales that are significantly different for the patients and their normative controls. Mean scores are provided for the age-specific US population norms of the whole group of 544 patients (Norm; mean age 60.4 years).
- Table S2. Quantitative data in support of Figure 2 (PDF file, 84 KB) -
This table provides the values for the mean scores on the SF-36 scales for the 251 treated patients at baseline, 1 year (n=104), and 2 years (n=84) after treatment. These are compared by one-sample t tests with US population norms for individuals in the same 10-year age ranges, and P values indicate those scales that are significantly different for the patients and their normative controls. Mean scores are provided for the age-specific US population norms of the treated patients (Norm; mean age 56.5 years).
- Table S3. Quantitative data in support of Figure 3A (PDF file, 84 KB) -
This table provides the values for the mean scores on the SF-36 scales for the patients who achieved a hematologic complete response (CR) as determined at 1 year after treatment at baseline (n=57), 1 year (n=41), and 2 years (n=36) after treatment. These are compared by one-sample t tests with US population norms for individuals in the same 10-year age ranges, and P values indicate those scales that are significantly different for the patients and their normative controls. Mean scores are provided for the age-specific US population norms of the patients achieving CR (Norm; mean age 55.3 years).
- Table S4. Quantitative data in support of Figure 3B (PDF file, 84 KB) -
This table provides the values for the mean scores on the SF-36 scales for the patients who did not achieve a hematologic complete response as determined at 1 year after treatment at baseline (n=88), 1 year (n=63), and 2 years after treatment (n=48). These are compared by one-sample t tests with US population norms for individuals in the same 10-year age ranges, and P values indicate those scales that are significantly different for the patients and their normative controls. For comparison, mean scores are provided for the age-specific US population norms of the patients not achieving CR (Norm; mean age 57.3 years).
|
|
